Loading patent…
AssigneeInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking University
InventorsRui Liu, Zhuorong Li, Li Zeng, Ting Sun, Mimin Liu, Junxia Zhang
Estimating the term…
A miRNA marker for the treatment and/or diagnosis of Alzheimer's disease (AD), and the miRNA marker is a miRNA23 cluster. The miRNA23 cluster is used in the diagnosis and treatment of AD. The expression of the miRNA23 cluster is detected using primers for the microRNA marker through AD model cells, AD model animals and natural aging animals, and blood of AD patients, and it is found that the expression of the miRNA23 cluster is significantly reduced during the progression of AD, which reduces neuronal apoptosis by inhibiting the GSK-3β-mediated tau protein phosphorylation. Therefore, the miRNA23 cluster can be used as a novel biomarker and therapeutic target for the early, non-invasive diagnosis and treatment of AD.
A method for treating a mouse with Alzheimer's disease (AD), comprising injecting adeno-associated virus (AAV) carrying hsa-miR-23b into the mouse with Alzheimer's disease (AD), wherein the hsa-miR-23b consists of SEQ ID NO:
Dependencies are inferred from the claim text.